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ABSTRACT 
Background 
There are currently no published data about inhibitor epidemiology in the South African 
haemophilia population. International published studies suggest that people of African 
descent may have a higher risk of developing inhibitors than other ethnic groups. The 
uncertainty about an associated risk to and inhibitor risk in the South African patient 
population motivated the research question in this study.  The majority of patients with 
haemophilia in South Africa are black. We set out to examine the relationship between 
inhibitor development and the presence of risk factors in our patient population. 
Materials and Methods: 
We conducted asingle center retrospective study at the Haemophilia Comprehensive Care 
Center of the Charlotte Maxeke Johannesburg Academic Hospital, South Africa, between 
January 1989 and January 2010. The study was approved by the University of the 
Witwatersrand Human Research Ethics Committee. People with haemophilia (PWH) born in 
the study period were identified in the centre database. All previously untreated patients 
(PUPs) with severe haemophilia A born betweenJanuary 1
st
1989 and January 1
st
 2010 were 
included. Data on treatment upto and ≥ 50 exposure days(ED) or inhibitor development were 
collected. All data on every reason for treatment and the clotting factor (CFC) used were 
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collected. Demographic information, family history of inhibitors, exposure days, type of 
treatment given, inhibitor test results, inhibitor risk factors, genetic analyses were extracted 
from the hospital patient records, clinical laboratory information system and genetic 
counselling files. Data was anonymized and coded prior to analysis. 
Results: 
Of the 117 files screened, 85 met the eligibility criteria. The race breakdown/ethnicity of the 
85 was 67% black, 29% white and 3% mixed race. The mean number of EDs was 143for the 
entire group while the mean number of EDs was 114 for the inhibitor patients with a range of 
30 to 498. Just over 17.6 %(15/85) developed inhibitors of which 80% were black, 13% white 
and 7% mixed race. From the 85 patients 15/85 developed an inhibitor of which 80% were 
low titre and 20% were high titre inhibitors. A positive family history of haemophilia was 
present in 60% of inhibitor patients. In the 37/85 patients with mutation results, 16 had 
Inversion 22 and 21 had other mutations. In this PUP cohort, none of the PWH with inversion 
22 developed inhibitors. None of the cohort patients were on CFC prophylaxis, used 
recombinant CFCs or switched CFCs during the study period. 
Conclusion 
The inhibitor incidence of 17.6% in ourblack patient cohort is similar to other studies and 
does not support the suggestion that patients from black ancestry have a higher inhibitor 
incidence when compared to other ethnic groups.  
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CHAPTER 1 
1.0 BACKGROUND 
Haemophilia is an inherited X-linked lifelong bleeding disorder which is due to a 
deficiency of coagulation factor VIII(FVIII) in haemophilia A and a deficiency of 
factor IX (FIX) in haemophilia B. The factor deficiency is a result of a number of 
genetic mutations which are well described in the literature.  Owing to these 
mutations, the inheritance pattern is X linked indicating that haemophilia almost 
exclusively affects males. Rare cases of girls with haemophilia have been described. 
In particular, this has been seen in the setting of non-random inactivation of the 
normal X chromosome, Turner Syndrome and homozygosity(1). Haemophilia affects 
1 in 5000 boys in Haemophilia A while for Haemophilia B, the incidence is 
somewhat lower with 1 in 30000 boys affected(1). 
 
Although novel therapeutic proteins have been introduced to the market, it is likely 
that these advances will take a few years before they reach resource constrained 
populations. In the interim, the standard of care of haemophilia continues to be the 
replacement of the deficient coagulation factor in order to stop or prevent bleeding. 
Both plasma derived and recombinant clotting factor concentrates (CFC) are reported 
to be safe and efficacious(2).  The main complication of this therapeutic strategy is 
the development of neutralizing antibodies against the infused CFC. This is 
described in 25-30% of patients(3). 
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Clinically, the presence of an inhibitor is suspected when the administration of a 
coagulation factor concentrate fails to trigger a haemostatic response. The diagnosis 
has to be made in conjunction with demonstrable laboratory evidence. In the 
laboratory, a clinically significant inhibitor is defined as that above 0.6 Bethesda 
Units(BU)(4). In comparison to FIX and other inherited coagulation factor 
deficiencies, inhibitors against FVIII are most commonly seen. 
 
Risk factors for inhibitor development are multifactorial and include patient and non-
patient related factors. Clinically significant patient related factors include ethnicity, 
the presence of genetic mutations, family history of inhibitor development and 
disease severity(5).  Non-patient related factors include the role played by the 
environment in inhibitor development. 
 
The development of inhibitors is known to occur during the first 50 exposure days in 
previously untreated patients (PUPs) in > 95% of the patients.  The incidence of 
inhibitors has been reported up to 25-30% of patients with severe disease (<1% of 
factor levels)(2). After 50 exposure days (ED) inhibitor development becomes rare, 
even more so after 150-200 ED(5, 6). 
 
Studies that included patients from North America have shown that haemophilia 
patients of African descent may have a higher risk of developing inhibitors than 
others(7, 8).  This was confirmed in an individual patient data meta-analysis that 
included patients both from the US and Europe and in the CANAL study(9, 
10).Based on these findings, the risk of inhibitors among people of African descent is 
at least twice the risk of people of European descent.  
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Experiences in South Africa, however, suggest that the incidence of inhibitors among 
people from African descent may not be higher than the incidence among other 
populations(11). Observed differences between incidences of inhibitors among the 
different races may be explained both by true genetic differences, but also by 
differences in treatment strategies or other non-genetic risk factors.  
 
1.1 PROBLEM STATEMENT 
There are currently no published data about inhibitor epidemiology in the South 
African haemophilia population.  
 
1.2 RESEARCH QUESTION AND OBJECTIVES 
 
1.2.1 Research Question 
 
What is the epidemiology of inhibitor development in patients with severe 
haemophilia A seen at Charlotte Maxeke Johannesburg Academic Hospital 
Haemophilia Comprehensive Care Center(CMJAH – HCCC). 
 
1.2.2 Specific Objectives 
 To determine the number of new severe haemophilia A factor VIII <1% patients born 
from January 1
st
 1989 to January 1
st
 2010. 
 To document inhibitor diagnoses made during the study period. 
 To document risk factors for inhibitor development in patients. 
 To examine the association between inhibitor risk factors and the development of 
inhibitor. 
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CHAPTER 2 
 
 
2.0 INTRODUCTION AND PATHOGENESIS OF INHIBITOR 
DEVELOPMENT 
 
The treatment of bleeding episodes with CFC in patients with severe haemophilia is 
associated with the development of neutralizing antibodies against the infused CFC. 
See figure 1.This complication is seen in up to ~33% of patients with severe 
haemophilia A and ~13% of those with non-severe haemophilia A(12). Studies show 
that many risk factors for inhibitor development are found in previously untreated 
patients (PUPs) when compared to previously treated patients (PTPs)(9, 13).Patients 
who have been exposed to CFC for less than 50 days are known as PUPs while those 
exposed for longer are known as PTPs(13). Particularly, the risk for inhibitor 
development is increased in the first 20 ED. 
 
These risk factors are multifactorial in origin and include those that are patient 
related and those that non-patient related and involve a complex interplay between 
cellular components, cytokines and immune regulatory components(14).  
 
Additionally, the infused CFC is regarded as the initial inducer of an immune 
response owing to its antigenic potential. In PUPs, dendritic cells are the professional 
antigen presenting cells (PAPCs) responsible for the presentation of the infused 
FVIII to the CD4 T cell lymphocytes. The process of presentation is carried through 
the major histocompatibility class(MHC) II molecules(14). In previously treated 
patients, this process is carried out by B-cell lymphocytes. Prior to this presentation 
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to the CD4 T cell lymphocytes, the infused FVIII protein is processed via 
endocytosis into a PAPC, a process facilitated via mannose-specific receptors. 
 
Following the presentation of the infused FVIII CFC by PAPCs, an immune 
response ensues and this is evidenced by the production of neutralizing antibodies 
against the infused CFC. Predominantly, these are polyclonal high affinity 
immunoglobulins (Ig) belonging to the IgG1 and IgG4 subtypes. Their epitopes are 
located on both heavy and light chains of FVIII with a preference for the A2 and C2 
domains(15). 
 
Steric hindrance is described as a process which results in the cessation of a chemical 
reaction which might be caused by a molecule’s structure. This process is the main 
mechanism through which the infused FVIII CFC is neutralized. Other mechanisms 
described as possible contributors include the formation of immune complexes as 
well as enhanced catabolism and hydrolysis(16). 
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Figure.1 Model of the formation of anti-FVIII neutralizing antibodies.The 
causative FVIII mutation and HLA class II will be the main contributors to the risk 
of development of antibodies; from very low risk (green) unlikely to experience any 
antibodies with commercially available FVIII concentrates to very high risk (red). 
The final immune response and outcome will then be fine-tuned by T-regulatory 
cells and a variety of immune regulatory molecules, the activity of which will be 
defined genetically by therapy-related factors and immune system challenges. 
Adapted from Astermark 2015 
 
These processes result in the blockage of functional epitopes which include 
coagulation FIX, phospholipid membrane and Von Willebrand factor interaction 
sites. Further, based on the kinetics of the inhibition, these inhibitors are broadly 
classified into two groups namely; type I inhibitors which follow a dose-dependent 
linear inhibition, which is common in severe haemophilia. The second group is type 
II inhibitors which have a more complex kinetic profile and completely inactivate 
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FVIII. Type II inhibitors are seen in the milder form of haemophilia or in those with 
acquired haemophilia(17). 
 
2.1 RISK FACTORS 
 
2.1.1 ETHNIC BACKGROUND 
 
 
Ethnicity is reported to be an independent risk factor for inhibitor development. 
Indications by a number of studies suggest that when compared to Caucasians, 
African-Americans, Hispanic and Latinos are noted to have a higher propensity to 
develop neutralizing antibodies against the infused CFC(18). In the South African 
population setting, black subjects, which included both adults and children, were 
found to have a statistically and significantly higher prevalence of inhibitor 
development than white patients, irrespective of the FVIII gene mutation 
status(19).In this cohort, which is comprised of a majority of black subjects, inhibitor 
incidence is not higher than what is reported elsewhere. 
 
2.1.2  GENETIC FACTORS 
 
 
The field of genetics remains a significant contender in inhibitor development. See 
Fig 2.  There are genetic variables concerned with the outcome of replacement 
therapy with CFC and the subsequent development of a clinically significant 
inhibitor. These include the presence of a causative gene mutation, the MHC class I 
and II phenotype, T cell receptor repertoire and polymorphisms of the genes coding 
for cytokines and immune regulatory molecules(20). 
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Relating to the type of mutation, in patients with nonsense and missense mutations, 
the risk of inhibitor development is higher when the mutation is located in the light 
chain of the FVIII protein than when it is located outside(21). Causative gene 
mutations may be further subdivided into high risk mutations as well as low risk 
mutations. High risk mutations are those that result in the complete absence of FVIII 
protein synthesis. Typically these would include large gene deletions, inversions and 
nonsense mutations(22). See Fig 3. These are associated with the absence of central 
tolerance and result in higher risk of inhibitor development than those that result in 
partial FVIII synthesis(21). Low risk mutations are likely to manifest as missense 
mutations, small insertions or deletions and splice site mutations(20). 
 
To date, studies support that central to the development of inhibitors, MHC 
molecules may be contributing in part. Studies of patients with haemophilia A and 
the intron 22 inversion, seem to suggest that specific alleles signatures were more 
frequently seen in patients with inhibitors(22). However, this finding was not 
reproducible in the Malmo International Brother Study (MIBS) (23).FVIII haplotype 
mismatches are other variables associated with genetic risk factors(24). 
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Figure 2. Genetics and inhibitor development. Summary of factors that may 
influence the risk of inhibitor formation in patients with haemophilia. Adapted from 
Astermark et al 2006 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Risk of inhibitor development according to F8 genotype. This is a 
summary of a meta-analysis and systematic review of 30 studies, 5383 patients of 
which 1029 had inhibitors. This figure highlights the F8 genotype against an Odds 
Ratio.Adapted from Gouw SC et al 2012 
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2.1.3 FAMILY HISTORY 
 
There is evidence to suggest that the risk of inhibitor development is higher in 
families where a positive family history is present than in those with a negative 
family history.See Table 1. Gill et al found inhibitors to be more prevalent in siblings 
(~50%) than in extended relatives (~9%)(25).This was also confirmed in the MIBS 
cohort where it was shown that the rate of inhibitor concordance between siblings 
was even higher (~78%)(26). 
 
Table 1. Family history of inhibitors. Adapted from Astermark et al 2001 and 
Gouw et al 2007. 
 
2.1.4 ENVIRONMENTAL RELATED FACTORS 
Environmental factors described in the literature include age at first exposure to 
CFC, the intensity of treatment, the presence of danger signs and periods i.e. surgery, 
vaccinations, infections etc, the type of utilized CFC as well as prophylaxis versus on 
demand therapy.  
Age at first treatment with CFC should be examined carefully as the present data is 
inconclusive. Earlier studies suggested that exposure before the age of 6 months was 
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associated with an increased incidence of inhibitor development(27). This finding 
was reciprocated in a European study where 81 patients were followed up for 16 
years. In this study, cumulative incidence of inhibitor development in patients who 
started factor replacement before the age of 6 months was ~34%(28). 
 
However, studies that followed this era of thinking did not confirm any correlation 
between the age at first exposure to CFC and development of inhibitors(29).Whilst in 
the CANAL study, a young age at first exposure to factor VIII was associated with 
an increased risk of inhibitor development, this association largely disappeared after 
adjustment for intensity of treatment(9). 
 
 For this reason, it is extrapolated that earlier studies were comprised of a few 
number of patients and thus could not be statistically representative of an entire 
population of haemophiliacs.   Patients who are started on regular prophylaxis at an 
early age have fewer inhibitors than those treated on demand(20). In fact, it appears 
that regular prophylaxis at an earlier age reduces the incidence of inhibitors by 
~60%(9). Tissue damage during surgical intervention causes inflammation and is 
likely to result inintensified regimens of CFC utilization. For this reason, it has been 
found that during these periods, surgical procedures and the associated intensity of 
CFC may lead to an increased risk of inhibitor development.  
There is no relationship between the type of CFC used and the development of 
inhibitors. Further, switching between plasma derived product to a recombinant 
product or vice versa is not associated with an increased risk of developing 
inhibitors. This has been investigated and published in the biggest study to date(9).  
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Nonetheless, black patients treated with FVIII CFC are twice as likely to develop 
inhibitors against the infused CFC. This is true in the context of mismatched FVIII 
CFC replacement therapy. It is known that black patients have a F8 genetic 
haplotype that is different to that of the infused CFC, resulting in an increased risk of 
inhibitor development against the infused CFC(30). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3 
 
3.0 PATIENTS AND METHODS 
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3.1 Ethical considerations 
Clearance from the University of the Witwatersrand Human Research Ethics 
Committee and Post Graduate Committee were obtained prior to study 
commencement. See appendix A. As this was a retrospective studywith no active 
therapeutic intervention, individual informed consent was not required.  
 
3.2 Sources of Data 
Sources of data included clinical patient files at CMJAH-HCCC, the NHLS clinical 
laboratory information system as well as the genetic counseling files kept at the 
CMJAH. 
 
3.3 Study population 
 
The study cases include previously untreated patients with severe haemophilia A 
seen at the CMJAH-HCCC and were born from January 1
st
 1989 to January 1
st
 2010 
who meet the eligibility criteria. From this cohort, 117 Files were examined. 85 were 
eligible while 32 did not meet the eligibility criteria. This is summarized in figure 4 
below. Reasons for not meeting the eligibility criteria ranged from patients whose 
records were incomplete, less than 30 ED and those born outside of the stipulated 
study period. 
 
 
 
 
 
 
Patient files 
N=117 
14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Number of eligible patient files 
 
3.4 Study design 
This study was a single centre retrospective cohort studywhich involved 
retrospective collection of demographic information, family history of inhibitors, 
inhibitor test results and other risk factors for the development of inhibitors. Only 
patients with ≥ 50 ED to clotting factor concentrate(CFC) were included. This 
information was extracted from the hospital patient records, clinical laboratory 
information system and genetic counselling files. Data was anonymized and coded 
prior to analysis. 
 
 
 
 
 
3.5 Inclusion criteria 
 
 Previously untreated severe haemophilia A (FVIII<1%). 
 Must have complete clinical records at the clinic especially for first exposure day and 
peak treatment at first exposure day. 
Eligible 
N=85 
Ineligible 
N=32 
 Incomplete records 
 <30 exposure days 
 Born outside stipulated 
study period 
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 Follow-up until at least 30 exposure days, but 50 ED is preferred. 
 Gene mutation results for factor VIII, although those without will be included. 
 
 3.6 Exclusion criteria 
 
 Patients who fall out of the stipulated study period. 
 Those with incomplete documentation.    
 Those with acquired haemophilia.  
Referred patients with an inhibitor or a significant bleed which could represent a 
potential bias. 
3.7 Data Collection 
Clinical information including demographic information, age at diagnosis, family 
history of haemophilia, family history of inhibitors, number of twins with the same 
deficiency, genetic analyses, number of exposure days, CFC utilized was extracted 
from the hospital records, genetic counseling files and clinical laboratory information 
system. This was transferred onto the clinical record form (CRF).  See appendix B. 
This raw data was then coded into an excel spread sheet and summarized into a 
single data set prior to analysis. This ensured that patient confidentiality was 
maintained at all times.  
 
 
3.8 Data Analysis 
Statistical analyses werecarried out in SPSS (Statistical Package for Social Sciences) 
version 13. The analysis involved the description of variables with mean, median, 
standard deviation, numerical variables and frequency distributions. These were 
arranged in tables, pie charts or bar graphs.Correlations (associations) between 
different variables and inhibitor development were examined and results presented in 
16 
 
table formats. The chi square test of independence was carried out to determine 
whether the associations between variables were statistically significant or not. All 
the statistical tests were carried out with a 5% significance level for the p-value.  
The odds ratio, being a measure of effect size, describing the strength 
of association or non-independence between two binary data values was calculated. 
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CHAPTER 4 
4.0 RESULTS 
4.1  DEMOGRAPHICS AND BASELINE PATIENT INFORMATION 
The mean age at diagnosis was +/- 2 years of age with the majority of participants 
being on on demand CFC.  
4.1.1  ETHNIC DISTRIBUTION 
The majority of the study participants 67.1%(n=57) were black, followed by 29,4% 
(n=25) white and lastly 3,5% (n=3) mixed race. See figure 5. 
 
Figure 5. Ethnic Distribution of the study cohort 
 
 
4.1.2 DIAGNOSIS OF HAEMOPHILIA 
Out of the 85 eligible participants, only a single participant was diagnosed prenatally 
with the parents opting to proceed with the pregnancy to term (See Table 2). The 
majority of the participants were diagnosed postnatally with the majority related to a 
positive family history (See table 3). 
 
 
 
 
25 (29,4%)
57 (67,1%)
3 (3,5%)
Ethnic group (n = 85)
White Black Mixed Race
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Table 2. Prenatal diagnosis 
 
 
Number of patients 
diagnosed prenatally 
(n) 
Percentage % 
 
Reasons for prenatal 
diagnosis 
1/85 1.2% Positive family history 
 
 
 
Figure 6. Reasons for diagnosis 
 
Other reasons for the diagnosis comprise ~10%. This is constituted of referrals from 
other health care providers~7% (n=6) and ~3.5% (n=3) diagnosed immediately post 
surgery. See figure 6. 
4.1.3 FAMILY HISTORY 
60% (n=51) of the participants had a positive family history of haemophilia and 40% 
(n=34) had no prior history of haemophilia in their families nor did they have it in 
their ancestry.  
 
Family 
History, 58%
Bleeding, 32%
Other, 10%
Reasons for diagnosis
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Table 3. Family history of haemophilia depiction 
 
 Number of patients 
with a positive family 
history of haemophilia 
(n) 
Percentage % 
Yes 51/85 60 % 
   
No 34/85 40% 
 
 
 
4.1.4 FAMILY MEMBERS WITH INHIBITORS 
Table 4. Family member with inhibitors 
 Number of family 
members with 
inhibitors (n) 
Percentage % 
Yes 3/85 3.5% 
   
No 82/85 96.5% 
 
 
4.1.5 PAIR OF TWIN WITH SAME DEFICIENCY 
Table 5 Pair of twin with the same deficiency 
 Number of a pair of 
twin with the same 
deficiency (n) 
Percentage % 
Yes 1/85 1.2% 
   
No 84/85 98.8% 
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4.1.6 TYPES OF GENETIC MUTATIONS 
 
 
Figure 7. Types of genetic mutations 
 
Just over 30, 5% (n=26) tested positive for intron 22 inversion mutation. This was 
followed by 13% (n=11) of participants showing positivity for exon 14 mutation. 
The majority of the participant’s genetic mutational analysis was unknown 44,7% 
(n=38). Of the patients that developed a clinically significant inhibitor (n=15/85), 
none had an inversion of intron 22 mutation. Around 7/15(46.6%) were unknown, 
2/15(13.3%) were positive for exon 14, 1/15(6.6%) were positive for exon 4 and 
exon 9 mutations respectively. The remaining 4/15 patients had no mutations 
detected.See table 8. The single Turner Syndrome patient is a female patient who 
phenotypically behaved like a severe haemophilia A. 
 
 
4.2 FIRST 50 EXPOSURE DAYS 
 
The majority of the participants received more than 50 exposure days of CFC on the 
total group (85 patients) with the average number of days being 142.83 ± 168.67.  
For the sub-population of patients (15/85) that developed a clinically significant 
Intron 22 
inversion
Exon 14
Intron 1 Exon 9 Exon 24 Exon 8 Exon 13
Turner 
Syndrome
Unkown
0
5
10
15
20
25
30
35
40
N
u
m
b
er
s 
(n
)
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inhibitor, the average number of ED was 114 with the least number of exposure days 
being 30 while the highest number of days was 498.  
 
 
Figure 8. Reasons for treatment 
 
Reasons for treatment in this patient cohort ranged from a few patients on long term 
prophylaxis (4.7%) and short term prophylaxis (5.8%) to those that required aversion 
of postoperative bleeding(2.4%).  See figure 8. The majority of the patients required 
treatment for spontaneous bleeding and these were treated on demand (87%). 
 
 
Figure 9. Location of bleeds 
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In the event of a spontaneous bleed, the affected locations included the knees 
(49.4%), ankles (51.7%) and elbows (34.1%). The remainder of the bleeding 
episodes occurred outside these commonly reported joints. Of note is that intracranial 
bleeding accounted for a small fraction of bleeding episodes in our cohort 
(10.5%).Bleeding was not confined to a single location only, some patients bled in 
more than a single area and some had a combination of areas that required CFC 
replacement at a single clinic visit. 
 
 
4.3 INHIBITOR DATA RESULTS 
4.3.1 INHIBITOR DEVELOPMENT 
A clinically significant inhibitor was noted in 17,6% (n=15) of the study cohort. See 
Table 6. 80% of the inhibitor patients had low responding inhibitors while 20% were 
high responding inhibitors.These participants were on demand CFC replacement 
having been exposed to replacement therapy for more than 50 days. There was no 
coincidence of inhibitor development with viral infections, and periods of surgical 
interventions. The noted inhibitors persisted during the follow up visits and resulted 
in participants being given a bypassing agent instead of CFC to avert a bleed. 
 
Table 6 Incidence of inhibitor development 
 
How many participants developed a 
clinically significant inhibitor (n) 
Percentage (%) 
  
15/85 17.6% 
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4.4 CORRELATION OF INHIBITOR DEVELOPMENT WITH RISK FACTORS 
 
Table 7 Correlation of inhibitor development with risk factors 
 
 
 
 2 patients had no known family history of inhibitors. 
 7 patients did not have mutational analysis results.
Results and 
variables 
Ethnicity Family 
history of 
haemophilia 
Family 
member 
with 
inhibitor 
Twin with the 
same 
deficiency 
Intron 22 
inversion 
mutation  
Other 
mutations 
Type of 
CFC 
Intensity of 
treatment 
Prophylaxis 
versus on 
demand 
Yes 12/15 (B) 
2/15  (W) 
1/15 (MC) 
9/15 
(60%) 
1/13 
(7.6%) 
0 0/8 
 
4/8 
(50%) 
All on 
Plasma 
derived  
CFC 
No Surgery All on on 
demand 
No N/A 6/15 
(40%) 
12/13 
(92.3%) 
 
15/15 8/8 
(100%) 
4/8 
(50%) 
- - - 
Odds Ratio 2.792 1 1.466 - <1 2.667 - - - 
P value 0.248 1 0.480 0.641 0.119 0.219 - - - 
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Just over 80% (n=12, P-value = 0.278) of the patients that developed a clinically 
significant inhibitor are black patients. This is followed by the white and mixed race 
patient population with 13,3% (n=2) and 6,6% (n=1) respectively. A strong family 
haemophilia is noted in 60% (n=9) of the inhibitor population. 
 
 
Table 8. Genetic mutations in inhibitor subjects 
Unknown Exon 14 Exon 4 Exon 9 No mutation detected 
7/15(46.6%) 2/15(13.3%) 1/15(6.6%) 1/15(6.6%) 4/15(26.6%) 
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CHAPTER 5 
 
5.0 DISCUSSION 
 
5.1 PROFILE OF THE STUDY COHORT 
 
 
This study cohort comprised of patients from CMJAH-HCCC. Black participants were in 
excess of 67% relative to the other ethnic populations present in South Africa.  A number 
of  published studies in inhibitor development have included a profile of Latinos, African-
Americans and Hispanics as the non-Caucasian component of their studies. In these 
studies, black subjects and Hispanics have a higher propensity to develop inhibitors than 
white patients(18,26,30). It may thus be argued that results extrapolated from these data 
may not be entirely representative of purely black patients. In this cohort the black 
participants are of 100% black ethnicity and do not represent a mixed race. While that may 
be the case, the findings in this cohort are similar to those published elsewhere. 
 
 
5.2 INHIBITOR EPIDEMIOLOGY 
 
The reported incidence of inhibitors varies from cohort to cohort and this cohort is not 
different. Here, I report an incidence of 17.6%. Another cohort within the South African 
context reported a lower incidence at 13%(19). While these incidences are slightly 
different in these cohorts, the risk factor profile remains unchanged. When compared to 
published international data, the South African context inhibitor incidence is lower. In 
earlier reports, inhibitor incidence was reported at 10-15% of patients receiving CFC (3). 
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In the CANAL study, the incidence of inhibitor development was reported at 24% (9), 
while the MIBS study reported higher incidences. Data from across the globe highlights 
the noted differences in composition and characteristics of study participants. This may 
explain the wide variation in inhibitor incidences. 
 
5.3 RISK FACTORS AND CORRELATION  
 
5.3.1 DISEASE SEVERITY 
 
Patients in this cohort were all of a severe haemophilia phenotype as dictated by the 
eligibility criteria. This is inclusive of all the patients that developed a clinically significant 
inhibitor in this cohort who comprised 17.6% of the study cohort. When compared to a 
number of published studies showing disease severity as one of the risk factors for 
inhibitor development in haemophilia, results in this cohort are not different. In particular, 
patients that have severe haemophilia have a greater propensity of developing inhibitors 
than those with a moderate and mild phenotype.  This is largely related to the underlying 
gene mutation where large mutations such as deletions lead to a complete halt in the 
production of FVIII and thus lead to inhibitor formation(31). Owing to some production of 
endogenous FVIII in the moderate and milder forms of haemophilia, there is less inhibitor 
formation in these patients. The reported incidence is estimated to be between 3-13%(32-
34). 
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5.3.2 GENETICS 
In this cohort, none of the inhibitor positive participants had intron 22 inversion mutation. 
This is possibly due to the fact that the mutational status of the majority of participants in 
this cohort is unknown. See Table 8. This is in contradiction of what has been reported in 
the literature where there is a strong correlation between inhibitor development and the 
presence of intron 22 inversion mutation.  Refer back to figure 3.In datapublished 
byLochan et al, another South African cohort, 20% of intron 22 inversion positive 
participants developed a clinically significant inhibitor, supporting other studies(35, 36). 
 
Causative genetic mutations form the cornerstone for inhibitor development in patients 
with haemophilia. A recent meta-analysis confirms that large deletions and nonsense 
mutations have higher inhibitor risk than those in patients with intron 22(21). While that 
may be the case, intron 22 inversion mutation has been described as the main mutation 
which when present results in inhibitor development.  
 
5.3.3 ETHNICITY 
Although this cohort is comprised of a small number of participants relative to other 
published studies, there is a reinforcement of the positive association between a strong 
ethnic background and inhibitor development. Approximately 80% of the participants that 
have developed a clinically significant inhibitor in this cohort are of the black ethnic 
background. In Lochan et al, a three-fold increase in inhibitor development was noted in 
black intron 22 inversion positive participants when compared with the white intron 22 
inversion positive counter parts. This may be attributed to differences in genetic haplotypes 
noted in the different ethnic groups as will be discussed under the section genetic 
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haplotypes below.  Additionally, there is data to suggest the presence of other genetic 
markers with ethnic variability that may play a role. These include HLA class II molecules 
and the polymorphic nature of the regulatory genes concerned with the immune 
system(37). 
 
5.3.4 FAMILY HISTORY 
Just over 60% of the participants who developed a clinically significant inhibitor had a 
positive family history of haemophilia in our cohort. The strong association of inhibitor 
development in families with a positive family history of inhibitors was examined in the 
MIBS study. The MIBS study noted inhibitor incidences in families with a positive family 
history of inhibitors at 48% when compared to those without(26). These findings have also 
been corroborated in other studies where a higher incidence of inhibitors has been seen in 
siblings with haemophilia than those without(9, 25). In this cohort, the single participant 
whose family member had an inhibitor did not develop an inhibitor.   
 
5.3.5 GENETIC HAPLOTYPES 
 
In South Africa, the majority of our patients are on plasma derived products. One may 
extrapolate that a haplotype mismatch in our patients may not explain the inhibitor risk. 
Further in another South African cohort, haplotypes 3 and 5 noted in a black population 
was associated with a 38% inhibitor development in keeping with what has been published 
before(19). 
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Current evidence talks to the importance of studying genetic haplotypes amongst the 
different ethnic groups as part of an attempt to dissect contributors to inhibitor 
development. Information on genetic haplotypes in this cohort is unknown as their 
investigation is beyond the scope of this study. Nonetheless, studies report that of the 
studied haplotypes, haplotype 3,4,5 are found in individuals of the black ethnic group 
while haplotype 1 and 2 are found in whites and recombinant replacement products(19). It 
is postulated that mismatches between recombinant products and endogenous haplotypes 
may be the mechanism for inhibitor development in black patients(19).   Published data 
from the Hemophilia Genetics Study (HIGS) Combined Cohort shows that while genetic 
haplotypes are likely to contribute to inhibitor development, FVIII gene mutation remains 
a significant predictor of inhibitor risk(24).   
 
5.3.6 PROPHYLAXIS VERSUS ON DEMAND THERAPY 
 
In this present cohort, all the patients that developed a clinically significant inhibitor were 
on on demand CFC replacement. In the CANAL cohort, regular prophylaxis was 
associated with a 60% reduction in inhibitor risk than the on demand arm. In fact, early, 
regular prophylaxis was suggested to be protective against the development of 
inhibitors(9). 
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5.3.7 RECOMBINANT VERSUS PLASMA DERIVED CFC   
 
In a South African population, there are no studies examining plasma derived CFC versus 
recombinant CFC. In fact, a few of the patients that are on the recombinant product are 
either sponsored within a trial setting or this product is being supplied by the medical 
insurance. It is therefore needless to mention that the participants in this cohort were on 
plasma derived CFC while a few were on a recombinant product. For that reason, these 
participants could not be compared. In the 17,6% that developed inhibitors in this cohort, 
none were on recombinant CFC. 
 
5.3.8 OTHER RISK FACTORS 
The majority of participants in this cohort had been exposed to CFC for more than 50 
EDs.The mean number of EDs was 143 for the total study participants and 114 EDs for 
inhibitor patients. Patients that developed inhibitors did so within the first 50 exposure 
days, in keeping with what the literature reports. Data suggests that the first 20 exposure 
days carry the highest risk of inhibitor development in severe haemophilia PUPs 
patients(38).  None of our patients developed a clinically significant inhibitor within the 
first 20 days of exposure to CFC. Thus routine surveillance should be carried out in these 
periods, particularly if intensive therapy is to be instituted. In our setting, routine inhibitor 
surveillance is carried out every 6 months or at any point in the care of the patient should 
clinical suspicion arise. 
Although a third of the inhibitor patients had various surgeries throughout this period, 
these were not performed around the time when an inhibitor was detected. This was thus 
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not a significant finding in this cohort. Further, none of the patients in this cohort were 
switched. 
 
5.4 LIMITATIONS OF THE STUDY 
 
While this study has clarified a few unanswered questions in our patient population, the 
following limitations should be noted: 
1)  This is a retrospective study, therefore gives a historical perspective of what 
inhibitor epidemiology was at the specific time period. With advances in healthcare 
systems, this is likely to have changed. 
 
2) This is a single center cohort and thus not fully representative of the entire 
haemophilia population in South Africa. 
 
3) Some of the mutational analysis data is unknown as some of these patients have 
never been investigated at initial centers where participants were first seen.  
Additionally, some of the patients have been counselled but choose not to proceed 
with testing owing to cultural beliefs. 
 
4)  The data is representative of participants on plasma derived products and not 
inclusive of those on recombinant products. 
 
5)  The data represents participants on on-demand CFC therapy and not inclusive of 
those on prophylaxis.  
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5.5 RECOMMENDATIONS 
 
Epidemiological data serves to educate the relevant structures in healthcare systems in 
better planning and providing resources for the care of patients with specific disease types. 
This data has certainly provided that information as the treatment of this sub-population of 
patients with bleeding diathesis is complicated and has cost implications.As this is a single 
centre cohort, a multicenter cohort in a South African setting may assist in better 
characterizing a more representative sample of the population.The migration of families 
from our neighbouring African countries implies that the existing data is probably not 
accurately representative of the on-going changes. For this reason another epidemiological 
study, prospectively may be advantageous. 
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5.6 CONCLUSION 
The research question in this study was to determine the incidence of inhibitors in a cohort 
of severe haemophilia A patients that were previously untreated at CMJAH-HCCC over a 
period of 21 years. 85 patients met the eligibility criteria. For the inhibitor patients, that 
comprised17.6%(15/85) of the study population,the mean number of EDs was 114.  80% 
were black, 13% white and 7% mixed race. 80% were low titre and 20% were high titre 
inhibitors.None of the patients were exposed to periods of intense CFC infusion.The 
inhibitor incidence in our  mainly Black patients is similar to other studies and do not 
support that patients from Black ancestry have a higher inhibitor incidence.  
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APPENDIX A: ETHICS CLEARANCE CERTIFICATE 
 
APPENDIX B 
DATA COLLECTION SHEET 
A. FORM1 : Baseline Data 
A1 Date of Baseline assessment  
A2 Date of Birth  
A3 Sex *   
 * Rare carrier can have severe hemophilia  
A4 Ethnic origin  
A5 Clotting activity & date of measurement  
A6 Pair of twin with same deficiency  
A7 Type of genetic  mutation   
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 B. FORM2 : DIAGNOSIS  
B1 Date of diagnosis and weight at diagnosis   
B2 Age at diagnosis/Prenatal diagnosis?  
B3 Reason of diagnosis  
B4 Additional bleeding disorders?  
B5 Any untreated bleeds prior to diagnosis?  
B6 Other diseases that may interfere in 
prognosis? 
 
 
C. FORM3: FAMILY HISTORY  
C1 Family history of haemophilia?  
C2 Brothers with haemophilia?  
C3 Carrier status of sisters?  
C4 Family members with inhibitors?  
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D. Form 4 : FIRST 50 EXPOSURE DAYS 
 fill in for every exposure day until number 50 or inhibitor development if 
earlier 
   
D1 Date of treatment  
D2 Number of exposure day (chronological)  
D3 Reason of treatment  
D4 In case of a bleed location  
  side   
  severity  
D5 Total number of units given  
D6 Name of the product  
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E. Form 5:  Special & inhibitor information 
 
 fill in from data of first treatment until date ED 50 or 
inhibitor development 
50 exposure days 
E1 Date first treatment  
E2 Date ED 50 or first positive inhibitor  
E3 Surgery in this period?  
 if yes date  
  type of surgery performed 
E4 Total number of days in hospital in this period  
E5 Inhibitor?  
 if yes first titer & date first positive 
  send all inhibitor result (also 
negative) to study staff 
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E6 Recovery measured?  
E7 Prophylaxis  started?  
 if yes give start 
DATE 
 
E8 Home treatment?  
 if yes since when?  
E9 Weight at time E1 (approximate)in kg  
 
 
 
 
 
 
 
 
 
 
 
